ABBV Stock Analysis: AbbVie | NYSE

Drug Manufacturers - General | NYSE, USA | Market Cap: 521.500m USD | 12M Return: 28.5% | US00287Y1091 | Charts, Fundamentals & Technical Analysis

Immunology, Oncology, Aesthetics, Neuroscience
Total Rating 62
Safety 59
Buy Signal 0.80
Biotechnology
Sub-Industry Rotation: +3.1
Market Cap: 521B
Avg Turnover: 1.42B
Risk 3d forecast
Volatility26.0%
VaR 5th Pctl4.21%
VaR vs Median-1.78%
Reward TTM
Sharpe Ratio0.96
Rel. Str. IBD90.7
Rel. Str. Peer Group76.3 pctl
Character TTM
Beta0.101
Beta Downside0.123
Hurst Exponent0.440
Choppyness20.2%
Drawdowns 3y
Max DD20.74%
CAGR/Max DD1.53
CAGR/Mean DD5.20
EPS (Earnings per Share) EPS (Earnings per Share) of ABBV over the last years for every Quarter: "2021-09": 3.33, "2021-12": 3.31, "2022-03": 3.16, "2022-06": 3.37, "2022-09": 3.66, "2022-12": 3.6, "2023-03": 2.46, "2023-06": 2.91, "2023-09": 2.95, "2023-12": 2.79, "2024-03": 2.31, "2024-06": 2.65, "2024-09": 3, "2024-12": 2.16, "2025-03": 2.46, "2025-06": 2.97, "2025-09": 1.86, "2025-12": 2.71, "2026-03": 2.65, "2026-06": 3.65, "2026-09": 3.82,
EPS CAGR: 0.89%
EPS Trend: 10.6%
Last SUE: 2.28
Qual. Beats: 1
Revenue Revenue of ABBV over the last years for every Quarter: 2021-09: 14342, 2021-12: 14886, 2022-03: 13538, 2022-06: 14583, 2022-09: 14812, 2022-12: 15121, 2023-03: 12225, 2023-06: 13865, 2023-09: 13927, 2023-12: 14301, 2024-03: 12310, 2024-06: 14462, 2024-09: 14460, 2024-12: 15102, 2025-03: 13343, 2025-06: 15423, 2025-09: 15776, 2025-12: 16618, 2026-03: 15002, 2026-06: 16990, 2026-09: 17404,
Rev. CAGR: 7.64%
Rev. Trend: 98.2%
Last SUE: 0.63
Qual. Beats: 0

Warnings

Altman Z'' In Financial Distress Zone
Below Avwap Earnings

Tailwinds

Rs Leader
Idiosyncratic Leader
Calm
Favorite

Seasonality 11.9 years of data, until 10/2026

Jan -3.3% 21
Feb +1.4% 14
Mar -1.2% 4
Apr +0.3% 0
May -1.3% 4
Jun -0.7% 0
Jul +1.2% 4
Aug -0.3% 0
Sep -0.8% 14
Oct +0.4% 0
Nov +4.1% 9
Dec +1.2% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: ABBV AbbVie

AbbVie Inc. is a research-based biopharmaceutical company that develops, manufactures, and commercializes medicines and therapies worldwide. The company operates across multiple therapeutic areas, including immunology (Skyrizi, Rinvoq), oncology (Imbruvica, Venclexta, Elahere, Epkinly, Emrelis), neuroscience (Vraylar, Duodopa, Vyalev, Botox Therapeutic), migraine (Ubrelvy, Qulipta), eye care (Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis), gastroenterology (Mavyret, Creon, Linzess/Constella), and medical aesthetics (Botox Cosmetic, Juvederm Collection). Headquartered in North Chicago, Illinois, AbbVie was incorporated in 2012.

The biopharmaceutical sector is characterized by heavy investment in research and development, long product development cycles, and reliance on patent protection for revenue generation. Major players in this space typically face significant revenue erosion when key drugs lose exclusivity, which is why diversification across therapeutic areas and a robust post-LOE pipeline (such as AbbVies Skyrizi and Rinvoq succeeding Humira) is central to the business model of large-cap pharmaceutical firms.

AbbVies portfolio spans both branded prescription pharmaceuticals and consumer-facing medical aesthetics, the latter operating on a different commercial model that targets elective procedures rather than insured medical treatment. This dual exposure to pharmaceutical and aesthetics markets is a relatively distinctive feature within large-cap biotech peers.

Headlines to Watch Out For
  • Skyrizi and Rinvoq revenue offsets Humira biosimilar decline
  • Botox and Juvederm aesthetics demand drives Allergan segment growth
  • Pipeline catalysts in oncology and immunology support long-term outlook
Piotroski VR-10 (Strict) 5.5
Net Income: 10.3b TTM > 0 and > 6% of Revenue
FCF/TA: 0.13 > 0.02 and ΔFCF/TA -1.92 > 1.0
NWC/Revenue: -8.52% < 20% (prev -18.19%; Δ 9.68% < -1%)
CFO/TA 0.14 > 3% & CFO 20.1b > Net Income 10.3b
Net Debt (70.1b) to EBITDA (25.2b): 2.79 < 3
Current Ratio: 0.87 > 1.5 & < 3
Outstanding Shares: last quarter (1.77b) vs 12m ago 0.0% < -2%
Gross Margin: 73.72% > 18% (prev 69.74%; Δ 3.98% > 0.5%)
Asset Turnover: 46.89% > 50% (prev 44.54%; Δ 2.34% > 0%)
Interest Coverage Ratio: 5.87 > 6 (EBIT TTM 17.5b / Interest Expense TTM 2.98b)
Altman Z'' 0.20
A: -0.04 (Total Current Assets 37.5b - Total Current Liabilities 43.1b) / Total Assets 148b
B: -0.11 (Retained Earnings -16.2b / Total Assets 148b)
C: 0.12 (EBIT TTM 17.5b / Avg Total Assets 141b)
D: -0.03 (Book Value of Equity -4.58b / Total Liabilities 152b)
Altman-Z'' = 0.20 = B
Beneish M -3.07
DSRI: 0.96 (Receivables 13.5b/12.8b, Revenue 66.0b/59.6b)
GMI: 0.95 (GM 69.74% / 73.72%)
AQI: 0.95 (AQ_t 0.71 / AQ_t-1 0.75)
SGI: 1.11 (Revenue 66.0b / 59.6b)
TATA: -0.07 (NI 10.3b - CFO 20.1b) / TA 148b)
Beneish M = -3.07 (Cap -4..+1) = AA
What is the price of ABBV shares?

As of November 21, 2026, the stock is trading at USD 286.20 with a total of 8,755,117 shares traded. Over the past week, the price has changed by -2.99%, over one month by -1.00%, over three months by +9.98% and over the past year by +28.47%.

Current recommended Stop Loss: 275.20 (which is 3.8% or 1.6 ATR below the current price).

Is ABBV a buy, sell or hold?

AbbVie has received a consensus analysts rating of 4.31. Therefore, it is recommended to buy ABBV.

  • StrongBuy: 16
  • Buy: 7
  • Hold: 5
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the ABBV price?
Analysts Target Price 311.8 8.9%
AbbVie (ABBV) - Fundamental Data Overview as of 17 November 2026
Market Cap USD = 521b (521b USD * 1.0 USD.USD)
P/E Trailing = 50.6055
P/E Forward = 18.1818
P/S = 7.8998
P/B = 50.4573
P/EG = 0.5936
Revenue TTM = 66.0b USD
EBIT TTM = 17.5b USD
EBITDA TTM = 25.2b USD
Long Term Debt = 72.2b USD (from longTermDebt, last quarter)
Short Term Debt = 8.67b USD (from shortTermDebt, last quarter)
Debt = 80.9b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 70.1b USD (calculated: Debt 80.9b - CCE 10.8b)
Enterprise Value = 592b USD (521b + Debt 80.9b - CCE 10.8b)
Interest Coverage Ratio = 5.87 (Ebit TTM 17.5b / Interest Expense TTM 2.98b)
EV/FCF = 31.35x (Enterprise Value 592b / FCF TTM 18.9b)
FCF Yield = 3.19% (FCF TTM 18.9b / Enterprise Value 592b)
FCF Margin = 28.59% (FCF TTM 18.9b / Revenue TTM 66.0b)
Net Margin = 15.67% (Net Income TTM 10.3b / Revenue TTM 66.0b)
Gross Margin = 73.72% ((Revenue TTM 66.0b - Cost of Revenue TTM 17.3b) / Revenue TTM)
Gross Margin QoQ = 75.38% (prev 74.74%)
Tobins Q-Ratio = 4.01 (Enterprise Value 592b / Total Assets 148b)
Interest Expense / Debt = 3.68% (Interest Expense 2.98b / Debt 80.9b)
Taxrate = 19.24% (2.47b / 12.8b)
NOPAT = 14.1b (EBIT 17.5b * (1 - 19.24%))
Current Ratio = 0.87 (Total Current Assets 37.5b / Total Current Liabilities 43.1b)
 Debt / Equity = -17.65 (negative equity) (Debt 80.9b / totalStockholderEquity, last quarter -4.58b)
 Debt / EBITDA = 2.79 (Net Debt 70.1b / EBITDA 25.2b)
Debt / FCF = 3.72 (Net Debt 70.1b / FCF TTM 18.9b)
Total Stockholder Equity = -5.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.35% (Net Income 10.3b / Total Assets 148b)
 RoE = -203.3% (negative equity) (Net Income TTM 10.3b / Total Stockholder Equity -5.09b)
 RoCE = 26.05% (EBIT 17.5b / Capital Employed (Equity -5.09b + L.T.Debt 72.2b))
RoIC = 12.85% (NOPAT 14.1b / Invested Capital 110b)
WACC = 5.58% (E(521b)/V(602b) * Re(5.99%) + D(80.9b)/V(602b) * Rd(3.68%) * (1-Tc(0.19)))
Discount Rate = 5.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.52 | Cagr: 0.03%
[DCF] Terminal Value 74.86% ; FCFF base≈19.2b ; Y1≈18.6b ; Y5≈18.4b
[DCF] Fair Price = 123.3 (EV 288b - Net Debt 70.1b = Equity 218b / Shares 1.77b; r=8.35% [WACC [floored]]; 5y FCF grow -4.13% → 2.50% )
EPS Correlation: 10.60 | EPS CAGR: 0.89% | SUE: 2.28 | # QB: 1
Revenue Correlation: 98.16 | Revenue CAGR: 7.64% | SUE: 0.63 | # QB: 0
EPS current Quarter (2027-03-31): EPS=3.44 | Chg30d=+3.00% | Revisions=+29% | Analysts=9
EPS current Year (2026-12-31): EPS=13.98 | Chg30d=+0.10% | Revisions=-44% | GrowthEPS=+39.8% | GrowthRev=+10.8%
EPS next Year (2027-12-31): EPS=16.20 | Chg30d=-0.14% | Revisions=+16% | GrowthEPS=+15.8% | GrowthRev=+9.1%
[Analyst] Revisions Ratio: -11% (up=22, down=28)